Podcasts about hcc

Eleanor Thompson, 79, the first Black member elected to the Beacon City Council, died Jan. 17. She was born April 23, 1946, the daughter of Rosalee Thompson, who in 1962 moved from Charleston, South Carolina, to New York City to provide opportunities for her daughters, Eleanor and Vera. Rosalee died in 2019. Eleanor earned a bachelor's degree in political science from Lehman College and, in 2000, a master's degree in education from Columbia University. She was a schoolteacher in New York City before moving to Beacon. After selling real estate for 18 years, she retired to Texas in 2010. Eleanor was elected as a Democrat in November 2001 to represent Ward 2, when she was 55, defeating Don Gallo, the Republican incumbent, 391-321. It was standing-room-only at her swearing-in, and the other officials sworn in that day, including Member-At-Large (and current mayor) Lee Kyriacou, all used the Thompson family bible. Eleanor was re-elected in 2003, then elected to an at-large seat in 2005 and 2007. She also ran for the state Assembly in 2006 but lost to incumbent Thomas Kirwan. In 2007, as a board member at the Howland Cultural Center, Eleanor envisioned a program that would connect communities through music. "When it comes to cultural diversity, we're all students," she said. Her advocacy led to the creation of the Gospel Cafe, according to HCC. Eleanor began painting, drawing and taking photographs at age 9. In an interview with the Poughkeepsie Journal in 2000, she recalled visiting her aunt and cousin in Newburgh and painting pictures of the Hudson River, of men and boys fishing on the banks and of the ferry. (She described herself as "a water person.") She said she had recently thrown herself into sculpture after taking a class at Columbia. "It was the best thing that happened to me," she said. She focused on female figures. "My whole thing is I want to give my sisters out there some recognition — the brown ones, the black ones, the white ones, the yellow ones — we are fantastic." With the support of longtime HCC director Florence Northcutt, Eleanor expanded the focus of art exhibits to include more women and artists of color. She contributed to shows such as Women Artists of the Hudson Valley in 2000 and A Celebration of Women of Color in the Arts in 2006. In 2019, she returned to Beacon with her grandson, Bobby, for The 25th Anniversary of African-American Artists in the Hudson Valley. In addition to her civic service, Eleanor co-founded the Young Artists' Mentoring Project; served as program director at the Martin Luther King Community Center; established a curriculum for the Partnership with Schools and Businesses; and was a dedicated member of the Beacon Light Tabernacle Seventh-day Adventist Church. Among her awards: the Empire State Federation of Women's Clubs' Community Award (2004), the Eleanor Roosevelt Legacy Award (2005), the Shirley Chisholm Legacy Award (2005) and the inaugural Beacon Community Award presented by Beacon City Concerned Citizens. A memorial service is scheduled for 1 p.m. on Sunday (March 1) at Beacon Light Tabernacle, 1568 Route 9D, in Wappingers Falls. Memorial donations may be made to the Howland Cultural Center (dub.sh/thompson-hcc).

Full article: Enhancing Capsule on Dynamic Liver CT: Association With Hepatocellular Carcinoma Diagnosis Using LI-RADS Version 2018 Should an enhancing capsule be handled differently from other LI-RADS major features? Jordan Kondo, MD, discusses this AJR article by Choi et al. that explores the impact on CT-based HCC diagnosis of proposed modified LR-5 criteria that give an enhancing capsule the same priority as other major features.

Daniel Mebius (43) kreeg begin 2024 de diagnose HCC (leverkanker). In eerste instantie leek een operatie uitzicht te bieden op genezing, maar helaas keerde de ziekte al snel terug.Op dit moment is er nog één kans op een langdurige toekomst voor Daniel: een levertransplantatie. In deze speciale aflevering van Kankerpraat praten we open en eerlijk over zijn situatie, zoals we dat de afgelopen periode (sinds mei 2024) al veel samen hebben gedaan.Maar deze keer is het anders. Omdat Daniel dringend op zoek is naar een levende donor, delen we zijn verhaal nu in podcastvorm met onze luisteraars. Wil je meer weten over donatie bij leven? Lees hieronder verder of neem rechtstreeks contact op:

Wait…what happened to the iconic "HCC"? In this episode of the "Money" Market Podcast, host Owen LaFave and Hillsborough College President Dr. Ken Atwater unpack why Hillsborough College dropped "Community" from its name and what that means for Tampa's economic future. From workforce pipelines – FinTech, AI, healthcare, and even drone technology – Hillsborough College is fueling Tampa Bay's workforce and innovation ecosystem. Plus, plot twist, Hillsborough College just entered into a Memo of Understanding (MOU) with the Tampa Bay Rays to explore building a new stadium and mixed-use district on the Dale Mabry campus, potentially creating thousands of jobs and redefining the campus footprint. Ken shares how the college partners directly with major employers, responds to real-time industry needs, and trains talent for jobs that exist right now. This conversation also tackles affordability, enrollment growth, and why two-year colleges educate more Floridians than state universities. Owen and Ken address the Dale Mabry campus headline buzz and what a potential Rays development could mean for students and the region. With a booming $1.3B economic impact and tuition frozen for a decade, Hillsborough College is quietly doing some of the most important work in the Bay area. If you care about jobs, growth, and where Tampa Bay is headed next, you won't want to miss this episode.   WATCH NEXT: THE HIDDEN COST OF GROWTH IN TAMPA WITH GARRETT GRECO https://youtu.be/B8KrG3r6mtY SUBSCRIBE: https://www.youtube.com/channel/UCz_7yNs7dOuyKApAkohqJIQ   Follow The "Money" Market Podcast here:  Spotify: https://open.spotify.com/show/6e7E0DaJZQkuw339G7nGI4?si=27d047641a1d4b17 Apple Podcasts: https://podcasts.apple.com/us/podcast/the-money-market-podcast/id1733948143 Instagram: https://www.instagram.com/moneymarketpodcast Facebook: https://www.facebook.com/moneymarketpodcast Website: https://moneymarketpodcast.com   The Bank of Tampa | Member FDIC

Rick Stroud and Steve Versnick on the Tampa Bay Lightning's comeback win over the Sabres as they have points in 19 of their last 20 games. Nikita Kucherov had another 4-point night and Darren Raddysh continues to bomb away from the point. Plus Rob Manfred and Governor Ron DeSantis support the Rays stadium at HCC in a press conference on Tuesday, Tom Moore packs his back to leave Tampa as retirement begins and we answer your mailbag question on the Bolts trade deadline needs Hosted on Acast. See acast.com/privacy for more information.

In this episode of Liver Lineup: Updates and Unfiltered Insights, hosts Kimberly Brown, MD, and Nancy Reau, MD, break down new research on liver transplantation, hepatocellular carcinoma (HCC), and the ongoing evolution of surveillance strategies in chronic liver disease. Drawing on their extensive experience as transplant hepatologists, Brown and Reau place new data into practical context, highlighting where evidence may meaningfully inform practice and where unanswered questions remain.Key episode timestamps:0:00:00 – Introduction0:00:19 – Frailty & Transplant Evaluation0:02:54 – How Centers Use Frailty Measures0:04:37 – Practicalities of the Six‑Minute Walk0:06:10 – MELD 3.0 and Sex/Size Disparities0:08:42 – Exception Points & Size Constraints0:10:05 – Need for a Dynamic MELD System0:10:19 – Immunotherapy as Bridge/Downstaging for HCC0:13:34 – Real‑World Use of IO Around Transplant0:15:22 – Managing Rejection Risk0:19:03 – MASLD Population & Surveillance Gaps0:20:21 – Adherence to HCC Surveillance0:22:42 – Practical Barriers: AFP, Ultrasound, Radiology Reports0:24:02 – Shift Toward Blood-Based Surveillance0:26:01 – How AFP-L3 and DCP Are Used in Practice0:27:39 – Rising AFP, Imaging Strategy & Broader Trend to Blood Tests0:28:27 – Guidelines vs Real-World Practice0:29:37 – Closing Thoughts on Guidelines & Early Detection

In this episode of Liver Lineup: Updates and Unfiltered Insights, hosts Nancy Reau, MD, and Kimberly Brown, MD, tackle a paradox that continues to define viral hepatitis care: despite curative therapies for hepatitis C and highly effective suppression for hepatitis B, global and domestic elimination goals remain out of reach. The conversation reframes viral hepatitis not as a “finished” chapter in hepatology, but as an ongoing public health challenge shaped by missed screening, gaps in linkage to care, and uneven adoption of evidence-based interventions.Key episode timestamps:0:00:00 – Hepatitis elimination gaps; dialysis-unit success; primary-care screening barriers.0:04:30 – Statins in HBV/HCV: reduced HCC/decompensation; safety in compensated disease.0:08:41 – GLP‑1 agonists: improved liver outcomes and cancer/cardiometabolic profile; safety concerns addressed.0:13:21 – HBV functional cure and Bepi: niche role, durability, small but meaningful responder group.0:19:28 – HBV/HDV: disease severity; new mAb + siRNA regimen; comparison with existing options; access issues.0:23:28 – Bulevirtide durability data; real‑world compassionate-use case with recompensation and early HCC.

Over Under, HCC update, and a QB redraft

Rich Hollenberg has a Happy Birthday message for Doug and thoughts on the HCC build

Rick Stroud and Steve Versnick on the news the Mike McDaniel is going to be the next Offensive Coordinator of the Chargers and not the Buccaneers. Plus Baker Mayfield doesn't like new Falcons Head Coach Kevin Stefanski, the Lightning win again over San Jose, NHL starting to build outdoor rink at Raymond James Stadium and HCC approves plan to pursue Rays Stadium deal. Hosted on Acast. See acast.com/privacy for more information.

Welcome to 2026, HCC!We're launching the year with a powerful new sermon series, The Shape of Sin, inspired by Timothy Keller's teachings on the seven deadly sins. Pastor Joel will open the series by examining the anatomy of sin, peeling back its layers so we can recognize it for what it truly is. Sin is more than a list of bad decisions - it subtly reshapes our hearts, redirecting what we love and redefining where we place our trust. Join us on this journey of honest reflection and renewed perspective. When we see sin clearly, it doesn't drive us into guilt - it leads us into freedom, clarity, and a deeper wonder at God's grace. As sin is revealed, grace becomes more beautiful, mercy more personal, and Jesus more worthy of our devotion. Let's begin 2026 with open eyes, humble hearts, and growing awe for the God who restores what sin distorts.

Rhodri Davies sy'n trafod y prif ddatblygiadau yn ystod 2025 gyda Glesni Phillips o HCC.

Testimony SundayThank you for joining us for a special service as we reflect on the overwhelming goodness of God. Hear heartfelt testimonies from members of HCC  - powerful stories of the Lord's faithfulness to save, provide, transform, and revive! Come, be encouraged, inspired, and reminded that God is still moving, still restoring, and still faithful in every season.

Join Dr Davis from the RBWH as we discuss SIRT, radiation segmentectomy when treating HCC. Covering response rates, curative vs palliative therapy and steps to performing SIRTFor further reading check out: https://pubmed.ncbi.nlm.nih.gov/38495257/

Mike Hoxter, CTO of Lightbeam Health Solutions, is focused on applying AI to population health management by using predictive models to enhance risk stratification for organizations with value-based care contracts. He emphasizes the importance of integrating social determinants of health along with clinical data to create more accurate predictive scores for patient outcomes, such as reducing hospital readmissions. AI enables a model to incorporate diverse data to derive more fine-tuned, actionable predictions. Mike explains, "We're really all for optimization in value-based care plans and care management. That's really our bread and butter, which is a pretty wide net. So we have a lot of large provider organizations in either CMS MSSP, ACO REACH, or a wide range of value-based care contracts with a lot of the commercial players. The Blues, Humana, Cigna, and Aetna all have value-based care plans that they have contracts with providers. So, optimizing for performance in those contracts. Anybody who works within those is our main clientele. We also have payers that are administering value-based care plans and some hospital systems as well." "If you're good at preventative healthcare, you prevent a lot of unnecessary healthcare. And so risk stratification is something that we do a lot of, and we use a lot of the standard models out there. We have Johns Hopkins embedded into our application. We have all of the different HCC models for Medicare Advantage, CDPs for Medicaid, but then also we have a suite of internal machine-learning-based models, which, I think, is funny - we've gotten to a point where there's such a thing as traditional AI, which is what it's called." #LightbeamHealthSolutions #PopulationHealth #ValueBasedCare #VBC #VBCEnablement #AI #SDOH #RemotePatientMonitoring #Providers #Payers #ACO lightbeamhealth.com Download the transcript here

Mike Hoxter, CTO of Lightbeam Health Solutions, is focused on applying AI to population health management by using predictive models to enhance risk stratification for organizations with value-based care contracts. He emphasizes the importance of integrating social determinants of health along with clinical data to create more accurate predictive scores for patient outcomes, such as reducing hospital readmissions. AI enables a model to incorporate diverse data to derive more fine-tuned, actionable predictions. Mike explains, "We're really all for optimization in value-based care plans and care management. That's really our bread and butter, which is a pretty wide net. So we have a lot of large provider organizations in either CMS MSSP, ACO REACH, or a wide range of value-based care contracts with a lot of the commercial players. The Blues, Humana, Cigna, and Aetna all have value-based care plans that they have contracts with providers. So, optimizing for performance in those contracts. Anybody who works within those is our main clientele. We also have payers that are administering value-based care plans and some hospital systems as well." "If you're good at preventative healthcare, you prevent a lot of unnecessary healthcare. And so risk stratification is something that we do a lot of, and we use a lot of the standard models out there. We have Johns Hopkins embedded into our application. We have all of the different HCC models for Medicare Advantage, CDPs for Medicaid, but then also we have a suite of internal machine-learning-based models, which, I think, is funny - we've gotten to a point where there's such a thing as traditional AI, which is what it's called." #LightbeamHealthSolutions #PopulationHealth #ValueBasedCare #VBC #VBCEnablement #AI #SDOH #RemotePatientMonitoring #Providers #Payers #ACO lightbeamhealth.com Listen to the podcast here

In this episode of Better Edge, Sean W. P. Koppe, MD, moderates a panel of Northwestern Medicine hepatologists as they discuss recent scientific updates from the American Association for the Study of Liver Diseases (AASLD) annual meeting held in November 2025. The conversation addresses key updates in the management of patients with cirrhosis, MASLD, HCC, alcohol liver disease, cholestatic liver diseases and autoimmune hepatitis that were presented at the meeting.

Elevate your practice from hepatocellular carcinoma (HCC) surveillance to prognosis by mastering liver-specific contrast magnetic resonance imaging (MRI) techniques. Credit available for this activity expires: [11/14/26] Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/liver-mri-news-front-lines-2025a1000vg7?page=1?ecd=bdc_podcast_libsyn_mscpedu

Send us a textCan one AI system learn from every organ — and teach us something new about all of them?In this edition of DigiPath Digest #31, I explore how artificial intelligence is transforming pathology across multiple organ systems, revealing connections that help us diagnose faster, more consistently, and more accurately than ever before.From glomerulonephritis to hepatocellular carcinoma, AI is no longer confined to a single specialty — it's becoming the connective tissue between them.What's Inside:1️⃣ AI for Bladder Cancer Classification We begin with a multicenter study validating AI models for urothelial neoplasm classification using over 12,000 whole-slide images. Both CNNs and transformer models achieved high accuracy (AUC 0.983, F1 score 0.9). I discuss why the F1 score matters — and what it tells us about model balance between sensitivity and specificity.2️⃣ AI in Colorectal Cancer Care Next, we explore multimodal AI — integrating histopathology, radiology, genomics, and blood markers to modernize colorectal cancer workflows. AI now helps detect adenomas, infer microsatellite instability (MSI) from H&E slides, and predict treatment outcomes. I highlight the critical need for external validation, interpretability, and governance as AI enters clinical use.3️⃣ AI for Glomerular Nephritis Diagnosis A deep learning model trained on over 100,000 kidney biopsy images identified four nephritis types — FSGS, IgA, MN, and MCD — with over 85% accuracy. This technology could ease workloads and improve turnaround time in renal pathology. Still, I share why AI support may feel both empowering and unsettling for many pathologists.4️⃣ AI in Liver Disease (MASLD & HCC) AI is advancing noninvasive fibrosis staging and risk prediction in liver pathology. From large consortia like NIMBLE and LITMUS to predictive models for HCC therapy response, AI is moving us closer to precision hepatology. I also discuss the challenge of translating these tools from research to regulatory approval.5️⃣ Lightweight AI for Domain Generalization Finally, we look at one of pathology AI's biggest challenges: domain shift — when a model trained on one scanner or staining style performs poorly elsewhere. The new Histolite framework shows how lightweight, self-supervised models can generalize across data sources — trading some accuracy for reliability in real-world use.My TakeawayAcross every study, a single message stands out: AI isn't replacing pathologists — it's amplifying our vision. By connecting kidney, colon, liver, and bladder insights, AI is teaching us that medicine works best when it learns across boundaries.Episode HighlightsBladder cancer AI validation (06:41)Multimodal colorectal AI (12:38)Glomerular nephritis deep learning (19:29)AI in liver pathology (29:55)Domain shift & Histolite framework (38:17)Halloween wrap-up + SITC preview (46:18)Join me next time for updates from the SITC 2025 Conference, where I'll be live at Booth 415 with Hamamatsu and Biocare, discussing how AI and spatial biology are converging to drive clinical utility.#DigitalPathology #AIinHealthcare #ComputationalPathology #CancerDiagnostics #LiverPathology #RenalPathology #FutureOfMedicine #DigiPathDigestSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

This Sunday at HCC, we continue our Seven Deadly Sins series by looking at Envy — the Green-Eyed Monster. Envy begins with comparison, grows through insecurity, and ends by stealing our joy, but gratitude breaks its grip. Join us as we learn how to recognize envy in our hearts, find contentment in Christ, and celebrate the blessings God has already given us.Our regular service is at 10am on Sundays. We are located at 304 E. Austin Ave in Hutto, TX. Can't make it in person? You are welcome to join us live on Facebook or YouTube. If you need prayer or you just need someone to talk to please reach out to us at prayer@huttocommunitychurch.org.HCC Website - HCC Facebook - HCC YouTube

We will break down the historical data from Fidelity to reveal how a government shutdown truly affects the stock market, fixed income, and the broader economy, and why your long-term strategy remains the best defense. Today's Stocks & Topics: Neptune Insurance Holdings Inc. (NP), Market Wrap, Coloplast A/S (CLPBY), Games Workshop Group PLC (GMWKF), Should You Panic? The Real Impact of a Government Shutdown on Your Investments, Sanofi (SNY), Key Benchmark Numbers: Treasury Yields, Gold, Silver, Oil and Gasoline, The Shutdown, United Parcel Service, Inc. (UPS), Kenon Holdings Ltd. (KEN), The KPP Newsletter, Ramaco Resources, Inc. (METC), Warrior Met Coal, Inc. (HCC), Sign of Short-Term Market Strains.Our Sponsors:* Check out Anthropic: https://claude.ai/INVEST* Check out Gusto: https://gusto.com/investtalk* Check out Progressive: https://www.progressive.com* Check out TruDiagnostic and use my code INVEST for a great deal: https://www.trudiagnostic.comAdvertising Inquiries: https://redcircle.com/brands

Initial Reactions to the Press Conference Excitement over finally hearing from ownership.Big question addressed: Are the Rays staying in the Tampa Bay area?New owner Patrick Zalupski confirms commitment to the region. Stadium Plans & Vision Zalupski's top priority: Building a new stadiumInspiration from Atlanta's Battery:Mixed-use development: hotels, bars, restaurants, retail, concert venues.Emphasis on creating a destination, not just a ballpark. Atlanta as the Model Turner Field to The Battery move: strategic & fan-focused.Success of moving closer to where the fanbase actually lives.Takeaway: Rays should apply the same approach. Site Challenges & Possibilities Target: 100+ acres of land – a tall order in Tampa.Areas discussed:Gaslight District – likely out.Steinbrenner Field area – possibly too small.HCC campus – enough land but unrealistic due to school presence.Raymond James area – intriguing, but complex.I-4 corridor / near Ybor / fairgrounds – promising due to accessibility.Oldsmar, outskirts, or near Lakeland – growing regions with fan potential. Data-Driven Decision Making Emphasis on studying demographics and fan location data.Go where the fans are – maximize attendance and long-term success. Timeline & UrgencyGoal: Open new stadium by 2029.Concerns about tight turnaround for:Stadium constructionMixed-use developmentHopeful, but realistic – planning must move quickly and efficiently. Interim Situation: Tropicana Field Tropicana Field remains the temporary home.Renovations help, but it's still outdated.Sympathy for the team and fans having to return there. Stadium Features Confirmed Enclosed fixed roof stadium (not retractable).Pros: AC stays.Cons: Still playing indoors.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the fastest-growing etiology of hepatocellular carcinoma (HCC). This work identifies novel gene and lipid associations in human MASLD-driven HCC that may be exploited for therapeutic benefit. Methods: Human HCC tumor (n=8) and adjacent non-tumor samples (n=8) were obtained from the Biospecimen Procurement and Translational Pathology Shared Resource Facility at the University of Kentucky Markey Cancer Center. All patients met cardiometabolic MASLD criteria and were negative for viral hepatitis. Hematoxylin and eosin (H&E) staining was used for pathological determination of tumor and adjacent nontumor tissue. Lipids were extracted using a methyl-tert-butyl ether extraction method and subjected to lipidomics by the West Coast Metabolomics Center. RNA was isolated and used for bulk sequencing. Data were analyzed using paired nonparametric analyses via a Wilcoxon or Mann-Whitney test, as appropriate. Results: Histological analysis by H&E showed significant lipid vacuole accumulation in HCC tumors relative to nontumor tissue. Lipidomic analysis revealed significant increases in long-chain nonesterified monounsaturated fatty acids (MUFAs; C16:1, C18:1, C20:1) and MUFA-enriched phospholipids (PC30:1, PC32:1, PE32:1, and PC36:1) in tumors relative to nontumor tissue. No significant differences were observed in nonesterified polyunsaturated fatty acids (PUFAs; C18:2, C20:4, and C22:6), PUFA-enriched phospholipids (C36:4, C38:4, C38:6, C40:6), or in fatty acid esters of hydroxy fatty acids (FAHFAs; C38:2, C38:4, C38:6). However, both MUFA- (C14:1, C18:1) and PUFA-enriched acylcarnitines (C18:2, C18:3) were collectively reduced in human tumors. Differential analysis of RNA sequencing revealed fatty acid oxidation genes (CPT1A, CPT2, ACADL, ACADM, ACADS, HADHA) were significantly reduced in tumor versus nontumor tissue. Further, genes involved in de novo lipogenesis were largely dysregulated (e.g. no differences in SREBF1 or FASN; increases in ACLY, ACACA, and SCD1; decreases in ACSL1) in tumor versus nontumor tissue. Conclusions: These results suggest human HCC tumors exhibit a reduced capacity to undergo mitochondrial β-oxidation resulting in accumulation of free and esterified MUFAs with concomitant reductions in MUFA-carnitines. Current studies are underway to determine the mechanisms by which impairment of hepatic MUFA catabolism via FAO promotes the development of HCC in mice.

Send us a textLast month, The Lancet posted online an article from Stine Johansen, Fredrik Åberg, Emmanuel Tsochatzis and Aleksander Krag, titled "Screening for Advanced Liver Disease." The article aims to update the Wilson and Jungner criteria, initially developed in 1960, to address modern needs and issues. In this conversation, Professor Krag and Dr. Johansen join Roger Green to discuss their article. There are many nuances and high points to cover in this thoughtful, fairly lengthy conversation, but one key point is that screening a mass population for HCC or cirrhosis has an entirely different set of issues and criteria compared to the screening usually discussed on this podcast, which involves identifying a population at increased risk for MASLD or MASH and screening them. Also, healthcare is far more expensive than it was in 1960 with a plethora of high-cost ways to diagnose, treat and manage patients.As a result, the authors started with the 10 Wilson and Jungner criteria and added eight more. During this conversation, Stine emphasizes the need for a comprehensive clinical trial on this issue, and all panelists agree that LiverAIM is likely to serve as the study.

9/5//25: Max Page w/ AAUP Pres Todd Wolfson who won lawsuit when court ruled Trump illegally froze research grants from Harvard. 1st Congressional District candidate Jeromie Whalen. Northampton at-large City Council candidate Meg Robbins. Paul Gulla of Michelson Gallery: A Month of Music (Art.) Donnabelle Casis w/ Dir Rachel Rushing of HCC's Taber Art Gallery.

9/5//25: Max Page w/ AAUP Pres Todd Wolfson who won lawsuit when court ruled Trump illegally froze research grants from Harvard. 1st Congressional District candidate Jeromie Whalen. Northampton at-large City Council candidate Meg Robbins. Paul Gulla of Michelson Gallery: A Month of Music (Art.) Donnabelle Casis w/ Dir Rachel Rushing of HCC's Taber Art Gallery.

9/5//25: Max Page w/ AAUP Pres Todd Wolfson who won lawsuit when court ruled Trump illegally froze research grants from Harvard. 1st Congressional District candidate Jeromie Whalen. Northampton at-large City Council candidate Meg Robbins. Paul Gulla of Michelson Gallery: A Month of Music (Art.) Donnabelle Casis w/ Dir Rachel Rushing of HCC's Taber Art Gallery.

9/5//25: Max Page w/ AAUP Pres Todd Wolfson who won lawsuit when court ruled Trump illegally froze research grants from Harvard. 1st Congressional District candidate Jeromie Whalen. Northampton at-large City Council candidate Meg Robbins. Paul Gulla of Michelson Gallery: A Month of Music (Art.) Donnabelle Casis w/ Dir Rachel Rushing of HCC's Taber Art Gallery.

9/5//25: Max Page w/ AAUP Pres Todd Wolfson who won lawsuit when court ruled Trump illegally froze research grants from Harvard. 1st Congressional District candidate Jeromie Whalen. Northampton at-large City Council candidate Meg Robbins. Paul Gulla of Michelson Gallery: A Month of Music (Art.) Donnabelle Casis w/ Dir Rachel Rushing of HCC's Taber Art Gallery.

Send us a text00:00:00 - Surf's Up: Season 6 Episode 13 Louise Campbell, Jörn Schattenberg and Roger Green continue their discussion of some major issues from earlier this year, while co-authors Aleksander Krag and Stine Johanset join Roger to discuss their recent publication in The Lancet, titled "Screening for Advanced Liver Disease." 00:04:45 - Major Issues of the First Six Months: Integrated Patient ManagementLouise drives this conversation based on two related issues she sees emerging: (i) increasing opportunities for motivated patients to manage their own health and (ii) managing the total patient in an environment where people may be taking incretin agonists as if they are consumer drugs. With increased access to scanning, providers can monitor patients (and patients can self-monitor) more closely. However, some of the issues a provider might find are tricky: patients who undertake what Louise describes as "the sneaky areas patients think are normal, but are probably contributing to disease" due to miseducation or no education on healthy eating and lifestyle, or patients purchasing and using incretin agonists through consumer channels, but possibly at subtherapeutic doses. Vigilance and probing are key here, but health systems will need to train more people on the types of probing that uncover underlying issues and behaviors that patients mistakenly believe to be healthy. 00:21:02 - Newsmakers: Aleksander Krag and Stine Johansen discuss Screening for Advanced Liver DiseaseLast month, The Lancet posted online an article from Stine Johansen, Fredrik Åberg, Emmanuel Tsochatzis and Aleksander Krag, titled "Screening for Advanced Liver Disease." The article aims to update the Wilson and Jungner criteria, originally developed in 1960, to address modern needs and issues. In this conversation, Professor Krag and Dr. Johansen join Roger Green to discuss their article. There are many nuances and high points to cover in this thoughtful, fairly lengthy conversation, but the key point is that screening a mass population for HCC or cirrhosis has an entirely different set of issues and criteria compared to the screening usually discussed on this podcast, which involves identifying a population at increased risk for MASLD or MASH and screening them. 00:54:42 - Major Issues of the First Six Months: Changes in US Health Policy and Potential for Dynamism in the In-Office Scanning Market Roger drives this conversation, focusing on two very different, yet very important issues: the first is the increasing dynamism of the in-office scanning market, with leader Echosens developing new products and services, while companies like e-Scopics, Sonic Incytes, and Mindray (Hepatus) are introducing new devices with competing profiles. Roger discusses the idea that some scanners keep all data resident in the machine, while others send it immediately to the cloud. Louise suggests that we should welcome any reliable scanning device to the market. Separately, he lists some concerns about how the Trump Administration's focus on cutting services to the poor, coupled with Robert F. Kennedy Jr.'s distrust of pharmaceuticals and mainstream health research, might limit the number of Americans with access to healthcare and the kinds of care they can access. At the end of this conversation, Roger asks Jörn and Louise what they consider major issues for the next six months.01:11:40 - Business Report and Wrap-Up

Coal remains central to both power demand (AI data centers, baseload needs) and steelmaking (met coal). Matt Warder, Publisher of The Coal Trader, outlines where the market sits in its cycle and how equities are positioning for the next leg higher. Key Points: Thermal vs met coal: distinct demand drivers (power vs steel). AI data centers + global power needs may keep coal in the mix. China still dominant near-term; India a key long-term growth driver. Coal cycles run ~5 years - next peak expected by 2026–27. Company catalysts: cost curves, production growth, buybacks, and dividends. Stocks discussed: AMR, HCC, METC, NRP, BTU, ARLP, CNR   Click the following links to keep up to date on the coal market and coal stocks  Substack - https://thecoaltrader.substack.com/ Podcast - https://clearcommodity.net/podcasts/the-coal-trader   Investment disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security. Investing in equities and commodities involves risk, including the possible loss of principal. Do your own research and consult a licensed financial advisor before making any investment decisions. Guests and hosts may own shares in companies mentioned.  

In today's episode, we spoke with Masatoshi Kudo, MD, about the evolving treatment landscape in hepatocellular carcinoma (HCC) and how recent comparative analyses are helping refine the use of first-line immunotherapy-based regimens. Dr Kudo is a professor and chairman in the Department of Gastroenterology and Hepatology at Kindai University Faculty of Medicine in Osaka, Japan.

Send us a text00:00:00 - Surf's Up: Season 6, Episode 11 This week, we modify our usual episode structure to focus on multi-metabolic practices and constructs. The multi-metabolic practices covered this week are run by non-hepatologists who have chosen to focus on the liver in a broader cardiometabolic context. They include two practices discussed during a two-part roundtable, one run by US gastroenterologist Dr. Karen Jerome-Zapadka and the EDOM practice in Spain, run by endocrinologists. The expert interview is with Dr. Emily Andaya, an internist who helms a cardiometabolic practice in Indiana, US, that focuses on the liver. 00:14:23 - Roundtable Part I: Groundbreaker and introductionThe core of the episodes started during the weekly groundbreakers, as guests began to describe the path that brought them from single-disease specialization to the broader multi-metabolic practice.. Immediately after the groundbreakers, participants describe their clinics today, including patient population and principles underlying their approach to treatment.00:26:15 - Roundtable Part II: Tools they useGuided by Louise, the specialists discuss the devices they use to screen and stage patients and the drugs they use to treat them. One interesting item that emerges is that EDOM relies on a 0-to-4 disease severity classification, but it does not align point-by-point with the 4-point fibrosis scale common in MASH. 00:40:28 - Roundtable Part III: Training Providers in the ClinicsLouise starts this segment by asking the EDOM team how they train practitioners in their clinic. EDOM trains practitioners in nutrition and technologists in the proper use of scanning devices. Karen comments that one big issue in re-training involves the length of visits: 15 minutes for a typical GI visit vs. 60 minutes for an initial multi-metabolic session and 30 minutes for follow-ups. Along with this, the information gathering technique are different.00:50:57 - Roundtable Part IV: Patient Health and Wrap-upLouise asks participants whether and how they have measured the impact the multi-metabolic approach has on patients' health (profound in both cases) and whether they are seeing an increase in HCC. Karen sees a difference among her long-term patients, while EDOM refers patients before their fibrosis reaches cirrhosis stage. In the last part of the episode, panelists share perspectives on how their initial specialties fit with the broader multi-metabolic practice and the kinds of impact they can have on patients.01:12:50 - Expert: Dr. Emily Andaya discusses US initiatives in multi-metabolic healthThis week's expert is Dr. Emily Andaya, an Indiana (US)-based internist whose practice has expanded to take on a multi-metabolic focus. She begins by discussing her recent attendance at the American Society for Preventive Cardiology (SPC) meeting in Boston, where she heard a talk by Dr. Christos Montzoros, an endocrinologist and multi-metabolic advocate, who emphasized the importance of incorporating the liver into preventive cardiology's focus. Louise and Emily agree that cardiometabolic focus involves evaluating general, overall health, but Emily discusses how this might require a deeper or broader testing protocol for each target organ. Emily describes the 4-point CKM scale and Louise asks how fibrosis or NAS scoring, as deployed in the MASH CRN system, might be valuable here. This is a far-ranging conversation, but one special point of interest involves the psychological benefit of telling a patient they need to treat one (multi-metabolic) condition, instead of separate heart, kidney, endocrinological and liver conditions, which might feel far more overwhelming. 01:48:48 - ConclusionBecause Roger is on vacation, there is no business report this week.

Can you manipulate blood flow in the tumor microenvironment to optimize drug delivery? In this episode of the BackTable Podcast, interventional oncologist Dr. Zachary Berman (UC San Diego) joins host Dr. Christopher Beck to discuss real-world applications of pressure-enabled drug delivery in local, regional liver-directed therapies like TACE and Y90.---This podcast is supported by:TriSalus Life Scienceshttp://trinavinfusion.com/---SYNPOSISThe conversation begins with an overview of the tumor microvascular environment, focusing on the abnormal nature of the new vessels that feed tumors. They then discuss the genesis of pressure-enabled drug delivery and the theory behind its efficacy. Dr. Berman explains the TriNav catheter's micro-valve design, its anti-reflux properties, and how these features enhance tumor drug delivery. He walks through his own procedure technique, comparing and contrasting it to standard embolization, and details the utility of pressure-enabled drug delivery in lobar radioembolization and larger tumors. They also explore the benefits of both balloon occlusion and microvalve catheters.Real-world cases—including neuroendocrine tumors, segmental HCC, and more—illustrate the thought process around when to use specialized technologies. The episode wraps up with a discussion of the future implications for this technology in other pathologies, cost considerations, and the potential for enhancing drug delivery with innovative approaches.---TIMESTAMPS00:00 - Introduction01:39 - The Tumor Microenvironment06:59 - Pressure-Enabled Drug Delivery Explained09:37 - Technical Aspects of Pressure-Enabled Catheters21:48 - Case 1: Grade 3 Neuroendocrine Tumor34:06 - Case 2: Hepatocellular Carcinoma with Tumor and Vein36:01 - Case 3: TACE for Segmental HCC in Decompensated Cirrhosis38:58 - Case 4: Large Heterogenous Cholangiocarcinoma40:40 - Case 5: Lobar Neuroendocrine Tumor42:38 - Case 6: Segmental HCC with Central Necrosis47:52 - Best Practices and Technical Considerations57:52 - Future Directions in Pressure-Directed Embolotherapy59:48 - Conclusion and Final Thoughts---RESOURCESJVIR 2024 Jaroch et al.:https://pubmed.ncbi.nlm.nih.gov/38969336/

Tired of chasing the next “quick fix” in diet culture? In this empowering episode of Dawnversations, I sit down with wellness expert Lindsey Kaszuba to talk about breaking free from the toxic cycle of diets, fads, and unsustainable weight loss trends like Ozempic. We dive into how to finally get off the hamster wheel and start tuning into your body—based on your lifestyle, your age, and your goals. Lindsey shares how to create realistic, sustainable habits that actually work long-term. No guilt. No shame. Just real talk about food, mindset, and self-trust.If you're done with diet drama and ready for a smarter, saner approach to wellness, this episode is for you!FIND LINDSEY HERE:Lindsey's Instagram @lindseykaszubahealthHealth Club Collective is a course & community focused on helping women unlock their healthiest weight yet and trust their body…beyond the scale. Learn more about HCC.Join Lindsey's Thrive Tribe email community#dietculture, #intuitiveeating, #ozempic, #weightlossjourney, #wellnesspodcast, #healthyhabits, #bodytrust, #sustainableweightloss, #midlifewellness, #ditchthediet, #nutritioncoach, #lindseykaszuba, #dawnversationspodcast, #mindbodyconnection, #realwellness, #healthylifestyle, #agingwell, #balancedliving, #habitsnothacks, #bodyrespect, #selfcare, #wellness #health

The automotive industry is undergoing a profound transformation that's reshaping how we think about careers in vehicle repair and maintenance. Gone are the days when becoming a mechanic simply meant learning from your dad in the garage. Today's automotive technicians need sophisticated computer skills alongside traditional mechanical aptitude.Hugh Mann from Houston Community College joins us to discuss the evolving landscape of automotive education and the lucrative career paths available to those with proper training. "You almost feel like you gotta have an IT degree to work on them sometimes," Hugh notes when discussing modern vehicles with their complex sensors and driver-assist features. Dealerships are competing fiercely for qualified technicians, driving up wages and improving working conditions - including the increasingly common air-conditioned repair shops replacing the sweltering environments of years past.One particularly fascinating insight reveals how HCC structures their educational programs to accommodate different career aspirations. Students can complete certificates in as little as two semesters or pursue associate degrees that open doors to management positions later in their careers. The diesel and heavy equipment specialties often command higher salaries than traditional automotive paths, with different pay structures that appeal to those seeking more predictable income.Beyond the educational discussion, we explore creative ways car enthusiasts are repurposing automotive components. Jeff shares fascinating examples of BBQ grills crafted from engine blocks, rims, and even entire vintage cars - each telling a story about automotive passion extending beyond the road. Marrs rounds out our journey with unique driving destinations around San Antonio, from the spectacular emergence of 15 million bats at Bracken Cave to the quirky Toilet Seat Art Museum created by a former plumber. Whether you're considering a career change, looking to understand the future of automotive repair, or simply love unique car culture stories, this episode offers valuable insights into how vehicles continue to shape our lives in unexpected waysBe sure to subscribe for more In Wheel Time Car Talk!The Lupe' Tortilla RestaurantsLupe Tortilla in Katy, Texas Gulf Coast Auto ShieldPaint protection, tint, and more!Disclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.---- ----- Want more In Wheel Time car talk any time? In Wheel Time is now available on Audacy! Just go to Audacy.com/InWheelTime where ever you are.----- -----Be sure to subscribe on your favorite podcast provider for the next episode of In Wheel Time Podcast and check out our live multiplatform broadcast every Saturday, 10a - 12noonCT simulcasting on Audacy, YouTube, Facebook, Twitter, Twitch and InWheelTime.com.In Wheel Time Podcast can be heard on you mobile device from providers such as:Apple Podcasts, Amazon Music Podcast, Spotify, SiriusXM Podcast, iHeartRadio podcast, TuneIn + Alexa, Podcast Addict, Castro, Castbox, YouTube Podcast and more on your mobile device.Follow InWheelTime.com for the latest updates!Twitter: https://twitter.com/InWheelTimeInstagram: https://www.instagram.com/inwheeltime/https://www.youtube.com/inwheeltimehttps://www.Facebook.com/InWheelTimeFor more information about In Wheel Time Car Talk, email us at info@inwheeltime.comTags: In Wheel Time, automotive car talk show, car talk, Live car talk show, In Wheel Time Car Talk

The balance between targeting tumor and sparing healthy liver is delicate. How do the experts do it? In this case-based review, Drs. Zach Berman (UC San Diego) and Tyler Sandow (Ochsner Health) join host Dr. Kavi Krishnasamy to walk us through real-world scenarios and share how they approach Y90 dose optimization. --- This podcast is supported by: Sirtexhttps://www.sirtex.com/ Medtronic Emprinthttps://www.medtronic.com/emprint --- SYNPOSIS First, the doctors review a case of HCC and discuss key lab values, like albumin, and their role in planning. They also break down how they manipulate variables like microsphere activity, perfusion density, and total dose to deliver a tumor dose of around 1,100 Gy. The doctors also challenge the standard perfused dose of 400 Gy for large tumors and share when they feel comfortable pushing beyond it. Next, they discuss nuances in treating portal vein tumor invasion and what decides which Vp classifications can be treated with Y90 or combination immunotherapy. A subsequent case involving a large central HCC tumor explores the risks of biliary stricture from high radiation and the challenge of missing tumor margins with overly selective catheterization. In the last case, the doctors discuss different scenarios in multifocal HCC liver lesions. Overall, the conversation explores different approaches based on tumor size, location, and patient liver function, and highlights the importance of multidisciplinary collaboration in optimizing patient outcomes. --- TIMESTAMPS 00:00 - Introduction and Case Overview01:28 - Patient Case Study - Hep C and Alcoholic Cirrhosis02:05 - Evaluating Liver Function and Treatment Approach04:50 - Tumor Dose and Perfusion Density15:49 - Portal Vein Tumor Invasion21:42 - Case Study: Large Central HCC Tumor Treatment22:19 - Challenges in Treating Large Central Tumors22:48 - Dosimetry Considerations and Biliary Strictures27:24 - Case Study: Assorted Multifocal HCC Lesions Scenarios

In this episode, Joseph W. Franses, MD, PhD; Neehar Parikh, MD, MS; and Mark Yarchoan, MD, share their thoughts on incorporating immune checkpoint inhibitors into the care of patients with HCC including:Clinical Considerations for Selecting First-line Immunotherapy Combinations for Metastatic HCCOverview of the Latest Data for the Combination of TACE With Immunotherapy (eg, EMERALD-1 Study of TACE and Durvalumab ± Bevacizumab for Unresectable HCC; and LEAP-012 Study of TACE + Lenvatinib + Pembrolizumab) Latest Clinical Data and Updates for Systemic Therapy in Patients With High-Risk Early HCCProgram faculty:Joseph W. Franses, MD, PhDAssistant Professor of MedicineSection of Hematology-OncologyUniversity of ChicagoChicago, IllinoisNeehar Parikh, MD, MSAssociate ProfessorLi Ka Shing Research Professor of HepatologyClinical Director of HepatologyMedical Director, Liver Tumor ProgramDivision of Gastroenterology & HepatologyUniversity of MichiganAnn Arbor, MichiganMark Yarchoan, MDAssociate ProfessorSidney Kimmel Comprehensive Cancer CenterJohns HopkinsBaltimore, Maryland Resources:To access the resources associated with this podcast discussion, please visit the program page to access a recording from a live webinar and a frequently-asked questions commentary on this topic.

For this week's episode I'm bringing you something a little different, but of such importance that I had to share it with my Off the Record audience: The massive audit expansion of Medicare Advantage announced by CMS. In case you missed it, CMS in May rocked the mid-revenue cycle industry with the unveiling of a startling mandate. It will hire 2000 medical coders, beef up its audit technology, and expand its current limited auditing scope from 60 Medicare Advantage Plans to some 550 plans nationwide in an attempt to check widespread allegations of HCC upcoding. My colleague Jason Jobes has been closely following the news and presented this topic in June—the most attended webinar Norwood has ever hosted. This is a replay of that very well-received show. It covers: The evolving risk adjustment landscape and the rise of Medicare Advantage CMS broad and bold audit scope and strategy  Best practice techniques to survive in risk adjustment and avoid potential risks Jason refers to several slides during the presentation, which you don't necessarily need, but if you'd like to follow along or see the exact references and data we've posted them to the Norwood website with a link in the show notes. Enjoy the show!  Show notes and resources View the webinar slides here (free; requires registration) Read the full CMS audit announcement. 

Liver cancer, especially hepatocellular carcinoma (HCC), remains a major health concern worldwide. In Latin America, the situation becomes more difficult due to limited access to advanced treatments and the high prevalence of underlying liver diseases. A recent research paper, published in Volume 16 of Oncotarget by researchers from Argentina, Brazil, Chile, and Colombia, offers valuable insights into how patients in the region respond to a widely used immunotherapy regimen. This real-world study explores both the effectiveness of treatment and the risks of immune-related side effects. Understanding Hepatocellular Carcinoma: Why It is So Difficult to Treat Hepatocellular carcinoma is often diagnosed at an advanced stage and frequently occurs in people with pre-existing liver conditions such as cirrhosis. Standard treatments like surgery or local therapies are not always possible in these cases. In recent years, the combination of two drugs—atezolizumab and bevacizumab—has shown promise in extending survival. However, most of the evidence comes from controlled clinical trials that may not represent the realities faced by healthcare providers and patients in Latin America. The Study: Immunotherapy for Hepatocellular Carcinoma in Latin America In a multicenter study titled “Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma,” led by Leonardo Gomes da Fonseca from Hospital das Clínicas, Universidade de São Paulo, Brazil, and Federico Piñero from Hospital Universitario Austral, Argentina, researchers aimed to fill that gap. The study included 99 patients with advanced HCC from Argentina, Brazil, Chile, and Colombia. All patients received the combination of atezolizumab and bevacizumab. The main objectives were to assess how frequently immune-related side effects, known as immune-related adverse events (irAEs), occurred and whether these events affected overall survival. Full blog - https://www.oncotarget.org/2025/07/02/immunotherapy-safety-for-hepatocellular-carcinoma-in-latin-america-insights-from-a-real-world-study/ Paper DOI - https://doi.org/10.18632/oncotarget.28721 Correspondence to - Federico Piñero - fpinerof@cas.austral.edu.ar Video short - https://www.youtube.com/watch?v=gk3oQwzIC-E Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28721 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, liver cancer, immunotherapy, adverse events, immunology, real-world To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Will single session Y90 become the standard of care for HCC and oligo-metastatic disease? Tune in to our third installment of Dosimetry University with interventional oncologists Drs. Tyler Sandow, Nima Kokabi, and Kavi Krishnasamy as they share their experiences and best practices in single session Y90 treatment. --- This podcast is supported by:Sirtexhttps://www.sirtex.com/ Medtronic Emprinthttps://www.medtronic.com/emprint --- SYNPOSIS The doctors discuss the application and workflow of single session Y90 therapy for primary and oligo-metastatic liver tumors. They discuss the latest data from various institutions, emphasizing reduced lung dose, lower time to treatment, improved cost-efficiency, and the advantageous safety profile associated with single session treatment. The discussion also covers ideal patient selection based on tumor location and vascular characteristics, the importance of cone beam CT, and how to identify red-flag features of vascular enhancement. Our panel then reviews key technical considerations for single session success, including the use of flow-modifying microcatheters, gelfoam, and strategies for flow redirection. The episode concludes with a case discussion to explore the best strategy for a large liver tumor, detailing the specifics of each treatment and the potential role of combined therapies to achieve better long-term outcomes. --- TIMESTAMPS 00:00 - Introduction 00:47 - Single Session Y90: Workflow and Benefits03:52 - Patient Selection04:31 - Tumor Location and Preferred Techniques14:31 - Reperfusion and Redirection Techniques 26:16 - Case Study: Large Tumor Treatment37:01 - Long-Term Outcomes and Surgical Considerations

In this episode of Value-Based Care Insights, host Daniel Marino explores the newly introduced the CMS Transforming Episode Accountability Model (TEAM)—a mandatory five-year, episode-based pricing model, informed by earlier initiatives from the CMS Innovation Center. Designed to cover high-volume, high-cost surgical procedures, TEAM represents a significant shift in how hospitals and providers approach bundled payments. Join Daniel and special guest Lucy Zielinski, an expert in value-based programs and HCC coding , as they unpack what the TEAM model entails and what participating hospitals must do to prepare for the January 1, 2026 implementation. Gain insights how this model influences financial performance, drives care coordination redesign, and introduces new incentives and penalties. Whether you are a healthcare leader, provider, or payer, don't miss this overview of one of CMS's initiatives shaping the future of value-based care.

Ep 130- Value-Based Shift: Inside the CMS TEAM Transformation On this episode Dan explores the newly introduced the CMS Transforming Episode Accountability Model (TEAM)—a mandatory five-year, episode-based pricing model, informed by earlier initiatives from the CMS Innovation Center. Designed to cover high-volume, high-cost surgical procedures, TEAM represents a significant shift in how hospitals and providers approach bundled payments. Join Dan and special guest Lucy Zielinski, an expert in value-based programs and HCC coding, as they unpack what the TEAM model entails and what participating hospitals must do to prepare for the January 1, 2026 implementation. Gain insights how this model influences financial performance, drives care coordination redesign, and introduces new incentives and penalties. Whether you are a healthcare leader, provider, or payer, don't miss this overview of one of CMS's initiatives shaping the future of value-based care. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

This summer at HCC, we're diving into "Trustworthy Sayings" — real talk from Paul that hits hard. Today we kicked it off with the powerful reminder: Jesus came to save sinners… not the cleaned-up version of you, but the real, messy you. Paul went from Christian killer to church planter, and his story shows us that no one is too far gone. Jesus meets us right where we are — with grace that overflows.Our regular service is at 10am on Sundays. We are located at 304 E. Austin Ave in Hutto, TX. Can't make it in person? You are welcome to join us live on Facebook or YouTube. If you need prayer or you just need someone to talk to please reach out to us at prayer@huttocommunitychurch.org.HCC Website - HCC Facebook - HCC YouTube

When Jose Perez finished high school in Massachusetts, he took the advice of counselors who advised him to check out the range of opportunities at his local community college. He says it's been all good - Jose has taken courses towards certification to become an educational paraprofessional, some music classes, an ASL course, and participates in several campus organizations and clubs, including the student senate. He's also dedicated to working with campus police on de-escalation techniques, as he himself experienced improper treatment when hospitalized. Jose has been enrolled in classes at HCC for a few years and takes the paratransit to campus, something he learned to do after the pandemic. Now he's looking forward to getting his certification so he can help students in the same transition program he used when charting a path from high school to vocational training. He's joined on this episode by Rebecca Leporati, a counselor at HCC, who explains the scope of degree and non-degree options for community college students. Support the show

SummaryIn this episode, the hosts discuss various pressing issues in healthcare, including the recent increase in CMS investigations into Medicare risk adjustment data, the challenges faced by providers in complying with insurance requests, and the implications of Medicaid eligibility changes. They also delve into the role of GLP-1 medications in weight loss and the importance of patient advocacy in navigating healthcare decisions. The conversation emphasizes the need for healthcare professionals to engage in meaningful dialogue with insurers and to advocate for their patients' needs.TakeawaysThe increase in CMS investigators for Medicare risk adjustment data is significant.Providers have the right to push back against unrealistic insurance requests.Medicaid is a state program designed for low-income individuals and specific groups.Work requirements for Medicaid eligibility are being proposed, affecting millions.GLP-1 medications are becoming popular for weight loss but come with high costs.Patients should advocate for themselves and ask questions about their treatment plans.Insurance companies often request excessive documentation, creating administrative burdens.The healthcare system is facing challenges with compliance and documentation accuracy.Understanding the implications of HCC coding is crucial for providers.The long-term effects of new medications are still largely unknown.

Send us a textDr. Nikhil Kapila joins Dr. Michael Koren on this live MedEvidence! presentation. Dr. Kapila, a liver disease specialist, explains why we can't live without our liver. The doctors review what the liver does, what can cause damage to the liver, and what can go wrong when the liver suffers damage. They also discuss the importance of early testing, treatment options for some conditions, and the importance of clinical research in pushing liver health forward.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

While on site at the 2025 Spring Meeting of the ABA Antitrust Law Section, the Our Curious Amalgam team recorded interviews with senior competition agency enforcers from all over the world, including Italy and Greece. In the first segment of this episode, Jaclyn Phillips interviews Saverio Valentino, Board Member of the Italian Competition Authority. Following that is the conversation between Panos Dimitrellos and Hara Nikolopoulou, Vice President of the Hellenic Competition Commission. Listen to this episode to hear what's been happening in their respective agencies, and what makes them happy outside of competition law. With special guests: Saverio Valentino, Board Member, Italian Competition Authority and Hara Nikolopoulou, Vice President, Hellenic Competition Commission Related Links: Italian Competition Authority Hellenic Competition Commission Hosted by: Alicia Downey, Downey Law LLC, Jaclyn Phillips, White & Case LLP, and Panos Dimitrellos, Secretariat Economists LLC

There are now multiple phase 3 studies on combination transarterial chemoembolization (TACE) and immunotherapy showing a significant benefit over TACE alone. How do these findings change the hepatocellular carcinoma (HCC) treatment algorithm? In this multidisciplinary episode of the BackTable Podcast, Dr. Richard Finn (Medical Oncologist at UCLA) and Dr. Julius Chapiro (Interventional Radiologist at Yale University) join host Dr. Chris Beck to discuss immunotherapy, TACE, emerging trends in HCC treatment, and the future of the field.---This podcast is supported by an educational grant from Guerbet.---SYNPOSISThe doctors highlight the importance of high quality clinical data and the pivotal studies shaping current best practices. They explore the role of the different players on the multidisciplinary team and compare the oncologic and radiologic perspectives. Additionally, they discuss the synergy between TACE and immunotherapy, the criteria for selecting appropriate treatments, and the ongoing need for research and collaboration.---TIMESTAMPS00:00 - Introduction 03:35 - HCC from an Oncologic Perspective 05:33 - Radiological Perspective on Liver Cancer06:50 - Referral Patterns and Organizing a Multidisciplinary Approach18:01 - Explaining TACE and Variations in the Procedure27:27 - Choosing the Right Procedure for HCC36:13 - Making a Decision on Medical Treatment Candidacy 42:23 - Importance of Data Driven HCC Treatment, Practical Insights, and Studies to Know55:30 - Planning an Approach for a TACE Procedure01:02:26 - Final Thoughts and Future Prospects in Liver Cancer Treatment---RESOURCESBarcelona Staging System:https://www.ncbi.nlm.nih.gov/books/NBK569796/table/Ch3-t0001/TRACE Trial:https://pubs.rsna.org/doi/full/10.1148/radiol.211806PREMIERE Trial:https://www.gastrojournal.org/article/S0016-5085(16)34971-X/fulltextEMERALD-1 Trial:https://ascopubs.org/doi/10.1200/JCO.2024.42.3_suppl.LBA432LEAP O12 Study:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02575-3/abstract

Hepatocellular carcinoma (HCC) disproportionately impacts underserved and minority populations, compounded by systemic barriers in care. These populations face increased risk factors yet often experience delayed diagnoses and limited access to specialists, leading to later-stage detection. In this episode, CANCER BUZZ speaks with Karen S. Waldrop, BSN, RN, OCN, ONN-CG, a GI oncology nurse navigator at UAB O'Neal Comprehensive Cancer, and Henry Rendon, a patient diagnosed with HCC in June 2023. Together, they share insights on the vital role of multidisciplinary teams and how nurse navigators can mitigate access barriers by improving patient outreach, facilitating access to care, and guiding patients through the complexities of the health care system.  “Karen, my nurse navigator, knew everything I was going through. She made sure everything was coordinated and ran smoothly. She communicated clearly and thoroughly every time. I never had to second-guess what was happening. She made sure I was prepared, not just once, but every step of the way.” - Henry Rendon, patient guest with HCC “At our institution, we have a clinic where the patient can see a medical oncologist, a liver medical physician, an interventional radiology specialist, a pharmacist… the whole gamut. If they need social work, we'll pull in social work. If they need palliative care, we'll pull in palliative care. And that's in one visit. For folks with transportation issues or those who live far away, it's truly the best way to get care.” - Karen S. Waldrop, BSN, RN, OCN, ONN-CG   Karen S. Waldrop, BSN, RN, OCN, ONN-CG GI Oncology Nurse Navigator UAB O'Neal Comprehensive Cancer Birmingham, Alabama   Henry Rendon Patient Guest, diagnosed with HCC Helena, Alabama   Additional Resources: Multidisciplinary HCC Care Effective Practices in Care Coordination - https://bit.ly/4lHTpbN HCC Education and Protocols to Advance Treatment through Integrated Collaboration - https://bit.ly/42GpatW Understanding practices and gaps in multidisciplinary hepatocellular carcinoma (HCC) care within the community oncology setting - https://bit.ly/3XT4k84 Building Multidisciplinary Care Capacity for People Impacted by Hepatocellular Carcinoma - https://bit.ly/44rgFUS